Literature DB >> 11029678

Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia.

J A Brandenburg1, T J Marrie, C M Coley, D E Singer, D S Obrosky, W N Kapoor, M J Fine.   

Abstract

OBJECTIVE: To describe the presentation, resolution of symptoms, processes of care, and outcomes of pneumococcal pneumonia, and to compare features of the bacteremic and nonbacteremic forms of this illness.
DESIGN: A prospective cohort study.
SETTING: Five medical institutions in 3 geographic locations. PARTICIPANTS: Inpatients and outpatients with community-acquired pneumonia (CAP). MEASUREMENTS: Sociodemographic characteristics, respiratory and nonrespiratory symptoms, and physical examination findings were obtained from interviews or chart review. Severity of illness was assessed using a validated prediction rule for short-term mortality in CAP. Pneumococcal pneumonia was categorized as bacteremic; nonbacteremic, pure etiology; or nonbacteremic, mixed etiology. MAIN
RESULTS: One hundred fifty-eight (6.9%) of 2,287 patients (944 outpatients, 1,343 inpatients) with CAP had pneumococcal pneumonia. Sixty-five (41%) of the 158 with pneumococcal pneumonia were bacteremic; 74 (47%) were nonbacteremic with S. pneumoniae as sole pathogen; and 19 (12%) were nonbacteremic with S. pneumoniae as one of multiple pathogens. The pneumococcal bacteremia rate for outpatients was 2.6% and for inpatients it was 6.6%. Cough, dyspnea, and pleuritic pain were common respiratory symptoms. Hemoptysis occurred in 16% to 22% of the patients. A large number of nonrespiratory symptoms were noted. Bacteremic patients were less likely than nonbacteremic patients to have sputum production and myalgias (60% vs 82% and 33% vs 57%, respectively; P <.01 for both), more likely to have elevated blood urea nitrogen and serum creatinine levels, and more likely to receive penicillin therapy. Half of bacteremic patients were in the low risk category for short-term mortality (groups I to III), similar to the nonbacteremic patients. None of the 32 bacteremic patients in risk groups I to III died, while 7 of 23 (30%) in risk group V died. Intensive care unit admissions and pneumonia-related mortality were similar between bacteremic and nonbacteremic groups, although 46% of the bacteremic group had respiratory failure compared with 32% and 37% for the other groups. The nonbacteremic pure etiology patients returned to household activities faster than bacteremic patients. Symptoms frequently persisted at 30 days: cough (50%); dyspnea (53%); sputum production (48%); pleuritic pain (13%); and fatigue (63%).
CONCLUSIONS: There were few differences in the presentation of bacteremic and nonbacteremic pneumococcal pneumonia. About half of bacteremic pneumococcal pneumonia patients were at low risk for mortality. Symptom resolution frequently was slow.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11029678      PMCID: PMC1495594          DOI: 10.1046/j.1525-1497.2000.04429.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  26 in total

1.  Diagnosis of pneumonia by cultures, bacterial and viral antigen detection tests, and serology with special reference to antibodies against pneumococcal antigens.

Authors:  L A Burman; B Trollfors; B Andersson; J Henrichsen; P Juto; I Kallings; T Lagergård; R Möllby; R Norrby
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 5.226

Review 2.  Community-acquired pneumonia.

Authors:  J G Bartlett; L M Mundy
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

3.  Microbial etiology of acute pneumonia in hospitalized patients.

Authors:  J H Bates; G D Campbell; A L Barron; G A McCracken; P N Morgan; E B Moses; C M Davis
Journal:  Chest       Date:  1992-04       Impact factor: 9.410

4.  The aetiology, management and outcome of severe community-acquired pneumonia on the intensive care unit. The British Thoracic Society Research Committee and The Public Health Laboratory Service.

Authors: 
Journal:  Respir Med       Date:  1992-01       Impact factor: 3.415

5.  The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland.

Authors:  M T Kauppinen; E Herva; P Kujala; M Leinonen; P Saikku; H Syrjälä
Journal:  J Infect Dis       Date:  1995-11       Impact factor: 5.226

6.  Community-acquired pneumonia: impact of immune status.

Authors:  L M Mundy; P G Auwaerter; D Oldach; M L Warner; A Burton; E Vance; C A Gaydos; J M Joseph; R Gopalan; R D Moore
Journal:  Am J Respir Crit Care Med       Date:  1995-10       Impact factor: 21.405

7.  Deaths in bacteremic pneumococcal pneumonia. A comparison of two populations--Huntington, WVa, and Stockholm, Sweden.

Authors:  A Ortqvist; M Kalin; I Julander; M A Mufson
Journal:  Chest       Date:  1993-03       Impact factor: 9.410

8.  A three-year study of severe community-acquired pneumonia with emphasis on outcome.

Authors:  J Rello; E Quintana; V Ausina; A Net; G Prats
Journal:  Chest       Date:  1993-01       Impact factor: 9.410

9.  Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.

Authors:  R Pallares; J Liñares; M Vadillo; C Cabellos; F Manresa; P F Viladrich; R Martin; F Gudiol
Journal:  N Engl J Med       Date:  1995-08-24       Impact factor: 91.245

10.  The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta.

Authors:  J Hofmann; M S Cetron; M M Farley; W S Baughman; R R Facklam; J A Elliott; K A Deaver; R F Breiman
Journal:  N Engl J Med       Date:  1995-08-24       Impact factor: 91.245

View more
  19 in total

Review 1.  Bacteraemic pneumococcal pneumonia: current therapeutic options.

Authors:  Charles Feldman; Ronald Anderson
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  Development and validation of a short questionnaire in community acquired pneumonia.

Authors:  R El Moussaoui; B C Opmeer; P M M Bossuyt; P Speelman; C A J M de Borgie; J M Prins
Journal:  Thorax       Date:  2004-07       Impact factor: 9.139

3.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

4.  Healthcare reconsultation in working-age adults following hospitalisation for community-acquired pneumonia.

Authors:  Priya Daniel; Thomas Bewick; Tricia M McKeever; Mark Roberts; Deborah Ashton; Daniel Smith; Lenny Latip; Wei Shen Lim
Journal:  Clin Med (Lond)       Date:  2018-02       Impact factor: 2.659

5.  Community-acquired pneumonia: symptoms and burden of illness at diagnosis among US adults aged 50 years and older.

Authors:  Kathleen W Wyrwich; Holly Yu; Reiko Sato; David Strutton; John H Powers
Journal:  Patient       Date:  2013       Impact factor: 3.883

6.  The prevalence of anemia and its association with 90-day mortality in hospitalized community-acquired pneumonia.

Authors:  Michael C Reade; Lisa Weissfeld; Derek C Angus; John A Kellum; Eric B Milbrandt
Journal:  BMC Pulm Med       Date:  2010-03-16       Impact factor: 3.317

7.  Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a beta-lactam versus a fluoroquinolone.

Authors:  Esther Calbo; Montserrat Alsina; Mónica Rodríguez-Carballeira; Josep Lite; Javier Garau
Journal:  Antimicrob Agents Chemother       Date:  2008-04-21       Impact factor: 5.191

8.  Can we predict which patients with community-acquired pneumonia are likely to have positive blood cultures?

Authors:  Samuel George Campbell; R Andrew McIvor; Vincent Joanis; David Graydon Urquhart
Journal:  World J Emerg Med       Date:  2011

9.  Bacteraemic pneumococcal pneumonia in COPD patients: better outcomes than expected.

Authors:  E Calbo; E Valdés; A Ochoa de Echagüen; A Fleites; L Molinos; M Xercavins; N Freixas; M Rodríguez-Carballeira; J Garau
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-04-10       Impact factor: 3.267

Review 10.  Serotype-independent pneumococcal vaccines.

Authors:  Eliane Namie Miyaji; Maria Leonor Sarno Oliveira; Eneas Carvalho; Paulo Lee Ho
Journal:  Cell Mol Life Sci       Date:  2012-12-27       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.